High-dose rifampin: potential for treatment shortening
|
|
- Harold Hutchinson
- 5 years ago
- Views:
Transcription
1 High-dose rifampin: potential for treatment shortening Martin Boeree, MD, PhD Associate Professor Radboud University Nijmegen Medical Centre Rob Aarnoutse, Georgette Plemper van Balen, Andreas Diacon, Rod Dawson San Francisco, September 8th, 2012
2 1959 rifampicin (US rifampin) was discovered; a hydrazone of rifamycine B; in 1967 orally available, FDA registration 1971
3
4 Reasons dosage RIF 600 mg Pharmacokinetic reasons Toxicity reasons Cost
5
6 Higher dose rifampicin (13 mg/kg) in Indonesia rifampicin plasma concentration (mg/l) standard dose group (rifampicin 10 mg/kg) high dose group (rifampicin 13 mg/kg) Ruslami et al. Antimicrob Agents Chemother time after dose (h)
7
8 What is the right dosage of rifampin?
9
10 The trial plan All trials will be performed at registration standard, GCP/GCLP compliant 1) Maximum Tolerated Dose (MTD) study (Cape Town and Stellenbosch) 2) Phase II trial 3 x 50 in Moshi and Bagamoyo, Tanzania; 10 mg/kg (600), 15 mg/kg (900), 20 mg/kg (1200) 3) Higher dosages in phase II according to the MAMS design in 7 sites in Tanzania and RSA
11 MTD study in mice (De Steenwinkel et. al.) MTD in mice was 160 mg/kg
12 HR1 study Title Design A Phase IIA Dose Ranging Trial to Evaluate the Safety, Tolerability, Extended Early Bactericidal Activity and Pharmacokinetics of Higher Doses of Rifampicin in Adult Subjects with Newly Diagnosed, Uncomplicated, Smear- Positive, Pulmonary Tuberculosis. Phase IIA, multiple dose rising study Treatment pre-treatment period 7 days monotherapy RIF 7 days combination (+HZE) therapy Control group 10 mg RIF/kg (n=8) Study groups 20, 25, 30 up to 35 mg RIF/kg (n=15, per RIF dose) Parameters Safety and tolerability (biochemistry, haematology, AEs) Pharmacokinetics (PK) EBA # Patients 68 Question What is the highest tolerated dose?
13
14 Grading according to CTCAE version 4.0
15 Arm Total Grade 1 AE Grade 2 AE Grade 3 AE Grade 4 AE Grade 5 AE Control mg RIF/kg mg RIF/kg mg RIF/kg mg RIF/kg
16 Grade 1 Adverse Events Arm Total Unrelated Possibly related Related Control mg RIF/kg mg RIF/kg mg RIF/kg mg RIF/kg
17 Grade 2 Adverse Events Arm Total Unrelated Possibly related Related Control mg RIF/kg mg RIF/kg mg RIF/kg mg RIF/kg
18 Grade 3 Adverse Events Arm Total Unrelated Possibly related Related Control mg RIF/kg mg RIF/kg mg RIF/kg mg RIF/kg
19 Pharmacokinetics Intensive PK sampling at day 7 (rifampicin) and at day 14 (RHZE) Intake of drugs with a standardized light breakfast sampling at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours measurement of total plasma concentrations with validated HPLC methods calculation of PK parameters using non-compartmental analysis
20 Results PK of rifampicin at day 14 Group AUC 0-24 (h* mg/l) Geometric mean Min - max 10 mg/kg (control) mg/kg mg/kg mg/kg Group Cmax (mg/l), normal range circa 8-12 mg/l Geometric mean Min - max 10 mg/kg (control) mg/kg mg/kg mg/kg
21 No ceiling in AUC/C max upon repeated dose increases Disproportional increase in AUC and C max (nonlinear PK): more than 7-fold increase in average AUC from 10 to 30 mg/kg Interindividual variability in PK: be aware of higher exposure in individual patients
22 Results PK of rifampicin at day AUC 0-24 (mg*h/l) Cmax (mg/l) AUC 0-24 (mg*h/l) C max (mg/l) Dose in mg/kg 0 Exposure at day 7 may be higher in view of auto-induction of rifampicin
23 Preliminary results TTP n Median baseline Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 control arm 8 0,0 0,0 0,0 7,6 5,8 7,6 5,8 8,1 20 mg RIF/arm 15 0,0 5,6 6,4 7,5 7,5 8,6 9,0 8,2 25 mg RIF/arm 15 0,0 5,2 5,8 7,3 7,2 8,0 7,9 8,5 30 mg RIF/arm 15 0,0 5,6 7,1 7,8 9,0 9,1 9,3 10,1 35 mg RIF/arm (n=14) 14 3,8 5,2 6,2 7,0 8,1 8,2 9,0 9,5
24 HR2 Moshi and Bagamoyo, Tanzania, study design
25 HR2 End of enrolment June 2012, end of follow-up december 2012, expected results march 2013
26 MAMS Multiple arm, multiple stage design Several combinations in phase II Several interim analyses Poor arms discontinue, better arms continue Phase III selection design
27 Start Recruitment of 1 st Interim Analysis 2 nd Interim Analysis End of Recruitment Control Regimen Novel regimen 1 Stop Novel regimen 2 Novel regimen 3 Stop Novel regimen 4 Stop Stage 1 Stage 2 Stage 3
28 MAMS in PanACEA Control: HRZE isoniazid (H), rifampicin Std (R), pyrazinamide (Z), ethambutol (E) (anticipated start Jan 2013) Experimental Arm 1: HRZQ isoniazid (H), rifampicin 10 mg (R), pyrazinamide (Z), SQ mg(Q) Experimental Arm 2: HR 20 ZQ isoniazid (H), rifampicin 20 mg (R 20 ), pyrazinamide (Z), SQ mg (Q) Experimental Arm 3: HR 20 ZM isoniazid (H), rifampicin 20 mg (R 20 ), pyrazinamide (Z), moxifloxacin (M) Experimental Arm 4: HR 35 ZE isoniazid (H), rifampicin 35 mg (R 35 ), pyrazinamide (Z), ethambutol (E)
29 Acknowledgements All PanACEA site collaborators Rob Aarnoutse, Georgette Plemper van Balen, Marloes Weijers, Jakko van Ingen, Dick van Soolingen, Melanie Wattenberg, Johan Mouton, RUNMC Andreas Diacon, Jeanine Du Bois, Armour Venter, University of Stellenbosch, RSA Rod Dawson, Kim Narunsky, UCT, Cape Town, RSA Patrick Phillips, Andrew Nunn, MRC, London, UK Stephen Gillespie, St Andrews, UK Michael Hoelscher, LMU, Munich, Germany Gibson Kibiki, Hadija Semvua, Charles Mthabo, KCRI, Moshi, Tanzania Cecil Magis, Wouter Hoefsloot, Dekkerswald and RUNMC
30 Thank you
Shorter TB regimens What is in de pipeline? Martin Boeree, Associate Professor Radboudumc, Nijmegen, the Netherlands Tuesday, 23 September, 2014
Shorter TB regimens What is in de pipeline? Martin Boeree, Associate Professor Radboudumc, Nijmegen, the Netherlands Tuesday, 23 September, 2014 Disclosures Clinical trials and studies funded by EDCTP,
More informationHigh-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial
High-dose rifampicin, moxifloxacin, and SQ19 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial Martin J Boeree*, Norbert Heinrich*, Rob Aarnoutse, Andreas H Diacon, Rodney
More informationA dose ranging trial to optimize the dose of rifampin in the treatment of tuberculosis
A dose ranging trial to optimize the dose of rifampin in the treatment of tuberculosis Journal: American Journal of Respiratory And Critical Care Medicine Manuscript ID: Blue-201407-1264OC.R2 Manuscript
More informationWhat He Said: Rifampin versus Rifapentine
What He Said: Rifampin versus Rifapentine Charles A. Peloquin, Pharm.D. Director Infectious Disease Pharmacokinetics Laboratory Professor, College of Pharmacy & The Emerging Pathogens Institute University
More informationAssessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatment
Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatment Sven O Friedrich*, Andrea Rachow*, Elmar Saathoff, Kasha Singh, Chacha
More informationPrinciples and practice of treating drug-sensitive TB
Principles and practice of treating drug-sensitive TB Brian Eley Paediatric Infectious Diseases Unit Red Cross War Memorial Children s Hospital Department of Paediatrics and Child Health University of
More informationNEW DRUGS FOR TUBERCULOSIS: THE NEED, THE HOPE AND THE REALITY
NEW DRUGS FOR TUBERCULOSIS: THE NEED, THE HOPE AND THE REALITY Neil W. Schluger, M.D. Professor of Medicine, Epidemiology and Environmental Health Sciences Columbia University Global tuberculosis incidence
More informationClinical pharmacology and therapeutic drug monitoring of first-line anti-tuberculosis drugs Sturkenboom, Marieke Gemma Geertruida
University of Groningen Clinical pharmacology and therapeutic drug monitoring of first-line anti-tuberculosis drugs Sturkenboom, Marieke Gemma Geertruida IMPORTANT NOTE: You are advised to consult the
More informationACCESS TO MEDICINES. Update on tuberculosis field activities
ACCESS TO MEDICINES Update on tuberculosis field activities Update on clinical activities 1/3 Latent TB Prevent study (S26) main study (8053 patients) PK substudy construction of a POPPK model Paediatric
More informationPAEDIATRIC TB TRIAL UPDATE
PAEDIATRIC TB TRIAL UPDATE ANNEKE C. HESSELING PROFESSOR IN PAEDIATRICS AND CHILD HEALTH DIRECTOR: DESMOND TUTU TB CENTRE DEPARTMENT OF PAEDIATRICS AND CHILD HEALTH STELLENBOSCH UNIVERSITY, SOUTH AFRICA
More informationImproving Translation in TB Drug Development Through Quantitative Modeling. CPTR Workshop 2016, Washington DC
Improving Translation in TB Drug Development Through Quantitative Modeling Lessons from Recent Phase III TB Trials CPTR Workshop 2016, Washington DC Christian Lienhardt Global TB Programme WHO, Geneva,
More informationPharmacokinetics and doses of antituberculosis drugs in children
Pharmacokinetics and doses of antituberculosis drugs in children HS Schaaf Desmond Tutu TB Centre Department of Paediatrics and Child Health Stellenbosch University Declarations I have no conflict of interest
More informationStatus of the TB Drug Pipeline: Clinical Candidates
Status of the TB Drug Pipeline: Clinical Candidates Ann M. Ginsberg, MD, PhD Global Alliance for TB Drug Development Open Forum III Delhi, India Global TB Drug Portfolio: 7 clinical candidates gatifloxacin
More informationNon-rifampin rifamycins in TB/HIV
Non-rifampin rifamycins in TB/HIV Richard E. Chaisson, MD Johns Hopkins University Center for TB Research Consortium to Respond Effectively to the AIDS-TB Epidemic Rifamycins for TB Inhibit bacterial DNA-dependent
More informationDevelopment of New Regimens for Tuberculosis Zhenkun Ma, Ph.D.
Development of New Regimens for Tuberculosis Chief Scientific Officer Global Alliance for TB Drug Development 40 Wall Street, 24th Floor New York, NY 10005 USA 1 Outline What are the unmet needs in TB
More informationFinal Results from Stage 1 of a Double-Blind, Placebo- Controlled Trial with TMC207 in Patients with Multi- Drug Resistant (MDR)
Final Results from Stage 1 of a Double-Blind, Placebo- Controlled Trial with TMC207 in Patients with Multi- Drug Resistant (MDR) Tuberculosis (TB). AH Diacon*, A Pym**, MP Grobusch, G. Churchyard, T De
More informationPharmacokinetics and pharmacodynamics of anti-tuberculosis drugs in patients with tuberculosis
Pharmacokinetics and pharmacodynamics of anti-tuberculosis drugs in patients with tuberculosis Julie B Prahl, MD, PhD International Reference Laboratory of Mycobacteriology, Diagnostics and Infection Control
More informationOverview. Therapeutic Window. Does drug concentration matter? Treatment of Tuberculosis Therapeutic Drug Monitoring
Treatment of Tuberculosis Therapeutic Drug Monitoring 2nd European Advanced Course in Clinical Tuberculosis Dr. JWC Alffenaar, clinical pharmacologist Dept Clinical Pharmacy & Pharmacology University Medical
More informationPZA: A New Look Based on RNASeq, the Hollow Fiber System, and Patient Level Data. Tawanda Gumbo
PZA: A New Look Based on RNASeq, the Hollow Fiber System, and Patient Level Data Tawanda Gumbo Office of Global Health University of Texas Southwestern Medical Center, Dallas, Texas The team: this work
More informationTreatment of Tuberculosis Therapeutic Drug Monitoring
Treatment of Tuberculosis Therapeutic Drug Monitoring 2nd European Advanced Course in Clinical Tuberculosis Dr. JWC Alffenaar, clinical pharmacologist Dept Clinical Pharmacy & Pharmacology University Medical
More informationHot Issues in Tuberculosis: Treatment of Latent TB Infection and New TB Drugs
Slide 1 Hot Issues in Tuberculosis: Treatment of Latent TB Infection and New TB Drugs Constance A. Benson, M.D. Professor of Medicine Division of Infectious Diseases University of California, San Diego
More informationSirturo: a new treatment against multidrug resistant tuberculosis
Sirturo: a new treatment against multidrug resistant tuberculosis TB is an on-going problem WHO estimated incidence of new TB cases 2009 Global Tuberculosis Control: WHO report 2010. Available at: http://www.who.int/tb/publications/global_report/2010/en/index.html
More informationThe treatment of patients with initial isoniazid resistance
The treatment of patients with initial isoniazid resistance 2011 INTERTB Meeting, St George s, London Patrick Phillips, MRC Clinical Trials Unit DA Mitchison, AJ Nunn. 21 st October 2011 Outline Background
More informationProblems, progress and evaluation of agents in clinical development ACCEPTED. Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
AAC Accepts, published online ahead of print on 15 December 2008 Antimicrob. Agents Chemother. doi:10.1128/aac.00749-08 Copyright 2008, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationMultiple Drug-resistant Tuberculosis: a Threat to Global - and Local - Public Health
Multiple Drug-resistant Tuberculosis: a Threat to Global - and Local - Public Health C. Robert Horsburgh, Jr. Boston University School of Public Health Background Outline Why does drug resistance threaten
More informationA Population Pharmacokinetic Model Incorporating Saturable Pharmacokinetics and Autoinduction for High Rifampicin Doses
A Population Pharmacokinetic Model Incorporating Saturable Pharmacokinetics and Autoinduction for High Rifampicin Doses Robin J. Svensson 1, Rob E. Aarnoutse 2, Andreas H. Diacon 3, Rodney Dawson 4, Stephen
More informationEfficacy and safety of high-dose rifampin in pulmonary tuberculosis: a randomized controlled trial
Efficacy and safety of high-dose rifampin in pulmonary tuberculosis: a randomized controlled trial Authors Gustavo E. Velásquez, 1,2 Meredith B. Brooks, 2 Julia M. Coit, 2 Henry Pertinez, 3 Dante Vargas
More informationPHARMACOKINETICS AND TOLERABILITY OF A HIGHER RIFAMPICIN DOSE VERSUS THE STANDARD DOSE ACCEPTED IN PULMONARY TUBERCULOSIS PATIENTS
AAC Accepts, published online ahead of print on 23 April 07 Antimicrob. Agents Chemother. doi:.1128/aac.0-06 Copyright 07, American Society for Microbiology and/or the Listed Authors/Institutions. All
More informationChildhood Tuberculosis in the Kilimanjaro region: lessons from the TB Program
Childhood Tuberculosis in the Kilimanjaro region: lessons from the TB Program Charles M. Mtabho Gibson S. Kibiki Constantine F. Irongo Martin J. Boeree Rob E. Aarnoutse Introduction Tuberculosis (TB) remains
More informationPharmacokinetics and safety of Moxifloxacin: Preliminary results of a dose escalation study
Pharmacokinetics and safety of Moxifloxacin: Preliminary results of a dose escalation study A.D. Pranger 1, W.C.M. de Lange 2, R. van Altena 2, P. van der Harst 3, M.P. van den Berg 3, D.R.A. Uges 1, J.G.W.
More informationActivity of PNU and its major metabolite in whole blood and broth culture models of TB
Activity of PNU 100480 and its major metabolite in whole blood and broth culture models of TB Paul Converse 1, Jin Lee 1, Kathy Williams 1, Opokua Amoabeng 1, Kim Dionne 1, Nicole Parish 1, Robert Wallis
More informationDrug Interactions with ART and New TB drugs: What Do We Know?
Drug Interactions with ART and New TB drugs: What Do We Know? HIV/TB Research Frontiers Meeting 20 th Conference on Retroviruses and Opportunistic Infections 3 March 2013 Presented by: Kelly Dooley MD,
More informationShort-term storage does not affect the quantitative yield of Mycobacterium tuberculosis
JCM Accepts, published online ahead of print on 23 January 2013 J. Clin. Microbiol. doi:10.1128/jcm.02751-12 Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 2 Short-term storage
More informationOutline 8/2/2013. PK/PD PK/PD first-line drug กก PK/PD กก
Pharmacokinetic and pharmacodynamic of anti- tuberculosis drugs Outline PK/PD PK/PD first-line drug กก PK/PD กก Concentration vs time in tissue and other body fluids Pharmacologic or toxicologic effect
More information5 th. SAN FRANCISCO, CA USA 8 September Program & Abstracts
5 th SAN FRANCISCO, CA USA 8 September 2012 Program & Abstracts 5 th SAN FRANCISCO, CA USA 8 September 2012 5 th International Workshop on Clinical Pharmacology of Tuberculosis Drugs 8 September 2012 San
More informationTB Updates for the Physician Rochester, Minnesota June 19, 2009
TB Updates for the Physician Rochester, Minnesota June 19, 2009 Recent Findings & Activities of the Tuberculosis Trials Consortium (TBTC) Bill Burman Denver TBTC Unit & Denver Public Health Recent findings
More informationThe clinical pharmacology and drug interactions of bedaquiline
7 TH FIDSSA 2017 The clinical pharmacology and drug interactions of bedaquiline Helen McIlleron Division of Clinical Pharmacology University of Cape Town 20 years 2 drugs conditional approval based on
More informationPlasma Drug Activity Assay for Treatment Optimization in Tuberculosis Patients
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Dec. 2011, p. 5819 5825 Vol. 55, No. 12 0066-4804/11/$12.00 doi:10.1128/aac.05561-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Plasma
More informationA population pharmacokinetic model for rifampicin auto induction
A population pharmacokinetic model for rifampicin auto induction Paolo Denti 1, Wynand Smythe 1, Ulrika SH Simonsson 2, Roxana Rustomjee 3, Philip Onyebujoh 4, Peter Smith 1, Helen McIlleron 1 1 Division
More informationMedian (Min Max) CVC 100 mg + EFV placebo + TDF/FTC (N=8) CVC 200 mg + EFV placebo + TDF/FTC (N=10) LLOQ=5.00 ng/ml Time (h)
600 Pharmacokinetics (Pk) of cenicriviroc (cvc) following 100 or 200 mg once-daily Dosing with open-label tenofovir / emtricitabine (tdf/ftc) in hiv-1 infected subjects enrolled in a Phase 2b study David
More informationClinical pharmacology and therapeutic drug monitoring of first-line anti-tuberculosis drugs Sturkenboom, Marieke Gemma Geertruida
University of Groningen Clinical pharmacology and therapeutic drug monitoring of first-line anti-tuberculosis drugs Sturkenboom, Marieke Gemma Geertruida IMPORTANT NOTE: You are advised to consult the
More informationCabozantinib (Cometriq )
Cabozantinib (Cometriq ) Workshop dose escalation EMA 4/5 Dec 2014 Frans Opdam, internist-clinical pharmacologist Clinical assessor, Dutch Medicines Agency Phase 3 Study XL184-301 (EXAM): Design Cabozantinib
More informationManagement of MDR TB. Dr Priscilla Rupali MD; DTM&H Professor and Head Department of Infectious Diseases Christian Medical College Vellore
Management of MDR TB Dr Priscilla Rupali MD; DTM&H Professor and Head Department of Infectious Diseases Christian Medical College Vellore Outline Global epidemiology of Tuberculosis Epidemiology of Tuberculosis
More informationEffect of a High-Calorie, High-Fat Meal on the Bioavailability and Pharmacokinetics of PA-824 in Healthy Adult Subjects
AAC Accepts, published online ahead of print on 26 August 2013 Antimicrob. Agents Chemother. doi:10.1128/aac.00798-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 2 3 4 5 6
More informationExperience with Pyrazinamide and Rifampin Regimens for Latent TB Infection
Experience with Pyrazinamide and Rifampin Regimens for Latent TB Infection Krista Powell, MD, MPH Co-Project Officer, National Surveillance for Severe Adverse Events Associated with LTBI Treatment Lead,
More informationPopulation pharmacokinetics and bacterial dynamics of sutezolid in patients with active tuberculosis
Population pharmacokinetics and bacterial dynamics of sutezolid in patients with active tuberculosis Kajal B. Larson 1, Kun Wang 1,2, Lisa Beth Ferstenberg 3, Carol Nacy 3 and Edward P. Acosta 1 1 Division
More informationNATIONAL TUBERCULOSIS CONTROL PROGRAMME- SCC AREA Quarterly Report on New and Retreatment Cases of Tuberculosis
NATIONAL TUBERCULOSIS CONTROL PROGRAMME- SCC AREA Quarterly Report on New and Retreatment Cases of Tuberculosis Patients registered during quarter* of 20 Name of area No.# Name of the Reporter Signature:
More informationLimited role of culture conversion for decision-making in individual patient care and for advancing novel regimens to confirmatory clinical trials
Phillips et al. BMC Medicine (2016) 14:19 DOI 10.1186/s12916-016-0565-y World TB Day RESEARCH ARTICLE Limited role of culture conversion for decision-making in individual patient care and for advancing
More informationNewer anti-tb drugs and regimens. DM Seminar
Newer anti-tb drugs and regimens DM Seminar 31-10-14 Why are newer drugs/regimens needed? Problems with current drugs/regimens Drug resistance Drug interaction of anti-tubercular drugs with ART Long duration
More informationPharmacology and Pharmacokinetics of TB Drugs Part I
Pharmacology and Pharmacokinetics of TB Drugs Part I Charles A. Peloquin, Pharm. D. Professor, and Director Infectious Disease Pharmacokinetics Laboratory College of Pharmacy and The Emerging Pathogens
More informationOvercoming the Challenges in Access to TB Drugs for Children
Overcoming the Challenges in Access to TB Drugs for Children Gregory L. Kearns, PharmD, PhD Professor of Pediatrics and Pharmacology, University of Missouri Marion Merrell Dow / Missouri Chair in Pediatric
More informationEvaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience
Eur Respir J 2011; 38: 888 894 DOI: 10.1183/09031936.00176610 CopyrightßERS 2011 Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience A.D. Pranger*, R. van Altena #, R.E.
More informationDosage and Administration
SIRTURO product information for healthcare providers 2 WARNINGS: An increased risk of death was seen in the SIRTURO (bedaquiline) treatment group (9/79, 11.4%) compared to the placebo treatment group (2/81,
More informationState of the State in TB Control
State of the State in TB Control Jason Stout, MD, MHS Wake County TB Medical Consultant NC TB Medical Director Division of Infectious Diseases, Duke University Medical Center Disclosures-Funding NIH (grant)
More informationPopulation pharmacokinetics of rifapentine and desacetyl rifapentine in healthy volunteers: nonlinearities in clearance and bioavailability
AAC Accepts, published online ahead of print on 10 March 2014 Antimicrob. Agents Chemother. doi:10.1128/aac.01918-13 Copyright 2014, American Society for Microbiology. All Rights Reserved. 1 2 Population
More informationTherapeutic TB vaccines Shortening Treatment for (DS- and) DR-TB?
Therapeutic TB vaccines Shortening Treatment for (DS- and) DR-TB? Mark Hatherill South African Tuberculosis Vaccine Initiative (SATVI) University of Cape Town, South Africa 1 1. The need for a therapeutic
More informationGlobal epidemiology of drug-resistant tuberculosis. Factors contributing to the epidemic of MDR/XDR-TB. CHIANG Chen-Yuan MD, MPH, DrPhilos
Global epidemiology of drug-resistant tuberculosis Factors contributing to the epidemic of MDR/XDR-TB CHIANG Chen-Yuan MD, MPH, DrPhilos By the end of this presentation, participants would be able to describe
More informationExposure to Rifampicin Is Strongly Reduced in Patients with Tuberculosis and Type 2 Diabetes
MAJOR ARTICLE Exposure to Rifampicin Is Strongly Reduced in Patients with Tuberculosis and Type 2 Diabetes Hanneke M. J. Nijland, 1 Rovina Ruslami, 4 Janneke E. Stalenhoef, 2 Erni J. Nelwan, 5 Bachti Alisjahbana,
More informationStudy Centers: This study was conducted in 2 centers in Italy.
Title of Trial: A randomised, double-blind, placebo-controlled, two-period, two-sequence-crossover interaction study to assess the effect of safinamide on levodopa pharmacokinetics in subjects with Parkinson
More informationArticles. Funding Global Alliance for TB Drug Development.
Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in
More informationIssues in TB Drug Development for Sensitive Disease - Clinical Development
Issues in TB Drug Development for Sensitive Disease - Clinical Development GATB Open Forum New Delhi, 5-6 May 2008 Christian Lienhardt, MD, DTM, MSc, PhD IRD, Paris, France & International Union Against
More informationIntervention thematic group strategic portfolio
Intervention thematic group strategic portfolio Stakeholders meeting 31 st January 2013 White Sands Hotel intv@ihi.or.tz Description of the Thematic Group Focuses on human populations Individually and
More informationTherapeutic Drug Monitoring for Improving TB Treatment Outcomes: A Concept for a Randomized Clinical Trial before Clinical Implementation
Therapeutic Drug Monitoring for Improving TB Treatment Outcomes: A Concept for a Randomized Clinical Trial before Clinical Implementation Randall Reves, MD, MSc TB Consultant Professor of Medicine and
More informationBiltstraat BJ Utrecht the Netherlands. ',-'% % Program & Abstracts.
XL Biltstraat 106 3572 BJ Utrecht the Netherlands www.virology-education.com ',-'%+3-0 97% www.virology-education.com 16 September 2011 Program & Abstracts 4 th International Workshop on Clinical Pharmacology
More informationNew TB Medications. National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention New TB Medications Neha Shah MD MPH Field Medical Officer Tuberculosis Control Branch California Department of Public Health Centers
More informationMultidrug-resistant tuberculosis in children
Multidrug-resistant tuberculosis in children James Seddon Clinical Lecturer Imperial College London UCL-TB and LSHTM TB Centre World TB Day 2015 24th March 2015 Outline Burden Recent studies Preventive
More informationAntituberculosis Chemotherapy
Antituberculosis Chemotherapy Progress in Respiratory Research Vol. 40 Series Editor Chris T. Bolliger Cape Town Antituberculosis Chemotherapy Volume Editors Peter R. Donald Tygerberg Paul D. van Helden
More informationTreatment of XDR-TB. Focus on the Nix-TB and ZeNix Trials. RESIST-TB Webinar 11 January 2018 Daniel Everitt, MD
Treatment of XDR-TB Focus on the Nix-TB and ZeNix Trials RESIST-TB Webinar 11 January 2018 Daniel Everitt, MD Global Alliance for TB Drug Development Outline of Discussion TB Alliance Approach to Treatment
More informationDrug Interactions Lisa Armitige, MD, PhD November 17, 2010
Substance Abuse and Tuberculosis Oklahoma City, Oklahoma November 17, 2010 Drug Interactions Lisa Armitige, MD, PhD November 17, 2010 Drug Interactions Lisa Y. Armitige, M.D., Ph.D. Medical Consultant
More informationOptimization of dosing regimens of isoniazid and rifampicin in children with tuberculosis in India
British Journal of Clinical Pharmacology ORIGINAL ARTICLE Br J Clin Pharmacol (2019) 85 644 654 644 Optimization of dosing regimens of isoniazid and rifampicin in children with tuberculosis in India Correspondence
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationTB-CHAMP A PHASE 3 CLUSTER RANDOMIZED TRIAL FOR PREVENTION OF TB IN CHILD HOUSEHOLD CONTACTS
TB-CHAMP A PHASE 3 CLUSTER RANDOMIZED TRIAL FOR PREVENTION OF TB IN CHILD HOUSEHOLD CONTACTS ANNEKE C. HESSELING RESIST TB WEBINAR 20 APRIL 2017 DESMOND TUTU TB CENTRE PROFESSOR IN PAEDIATRICS AND CHILD
More informationPharmacokinetics (PK) and Pharmacodynamics (PD) in the Treatment of Tuberculosis
Pharmacokinetics (PK) and Pharmacodynamics (PD) in the Treatment of Tuberculosis Shaun E. Gleason, PharmD, MGS Associate Professor, Department of Clinical Pharmacy Director, Distance Degrees and Programs
More informationCurrent Status in the Development of the New Anti-Tuberculosis Drugs
National Scientific Meeting TB UPDATE IX 2017 WORKSHOP AND SYMPOSIUM Novel Management to End TB Hotel Bumi Surabaya 29-30 April 2017 Current Status in the Development of the New Anti-Tuberculosis Drugs
More informationTB ReFLECT Meta-Analysis of Fluoroquinolone-Containing Regimens for the Treatment of Drug-Susceptible TB
TB ReFLECT Meta-Analysis of Fluoroquinolone-Containing Regimens for the Treatment of Drug-Susceptible TB Rada Savic, PhD Medical Consultant Meeting San Antonio, TX November 29-30, 2018 1 EXCELLENCE EXPERTISE
More informationImpact of the interaction of R with rifampin on the. treatment of tuberculosis studied in the mouse model ACCEPTED
AAC Accepts, published online ahead of print on 21 July 2008 Antimicrob. Agents Chemother. doi:10.1128/aac.00566-08 Copyright 2008, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationJeffrey R. Starke, M.D. has the following disclosures to make:
AAP 2018 Red Book Tuberculosis: IGRAs and Treatment of TB Infection Jeffrey R. Starke, M.D. May 31, 2018 AAP 2018 Red Book Childhood Tuberculosis: IGRAs and Treatment of TB Infection May 31, 2018 WEBINAR
More informationHIV-TB co-infection: overview and recent update
HIV-TB co-infection: overview and recent update Brian Eley Paediatric Infectious Diseases Unit Red Cross War Memorial Children s Hospital School of Child and Adolescent Health University of Cape Town HIV
More informationThe early bactericidal activity of anti-tuberculosis drugs: a literature review
Tuberculosis (2008) 88 Suppl. 1, S75-S83 The early bactericidal activity of anti-tuberculosis drugs: a literature review P.R. Donald a,c, *, A.H. Diacon b,c Departments of a Paediatrics and Child Health,
More informationApplication for addition of 3-FDC rifampicin 150/isoniazid 75/ethambutol 275 mg (RHE) to the WHO model list of essential medicines
Application for addition of 3-FDC rifampicin 150/isoniazid 75/ethambutol 275 mg (RHE) to the WHO model list of essential medicines Geneva, 10 August 2006 Focal Point: Hugo Vrakking Global Drug Facility
More information2401 Gillham Road Kansas City, Missouri Phone (816)
2401 Gillham Road Kansas City, Missouri 64108 Phone (816) 234-3000 www.childrens-mercy.org Children s Mercy Hospitals and Clinics Division of Clinical Pharmacology and Medical Toxicology CPMT Project.:
More informationStandard TB Treatment
Standard TB Treatment Chris Keh, MD TB Controller, TB Prevention and Control Program, San Francisco Department of Public Health Assistant Clinical Professor, Division of Infectious Diseases, University
More informationConcentration-Dependent Antagonism and Culture Conversion in Pulmonary Tuberculosis
Clinical Infectious Diseases MAJOR ARTICLE Concentration-Dependent Antagonism and Culture Conversion in Pulmonary Tuberculosis Neesha Rockwood, 1,2 Jotam G. Pasipanodya, 3 Paolo Denti, 4 Frederick Sirgel,
More information"Sterilization of TB disease in
11/1/1 "Sterilization of TB disease in mice " Jacques Grosset Pharmacodynamics of daily rifapentine and rifampin in mice Free rifam mycin Concentrati ion/mic 1 1 Rifapentine (1mg/kg) Free rifam mycin Concentrati
More informationGeneric lopinavir/ritonavir is bioequivalent to Aluvia but neither result in adequate lopinavir exposure at 50% dose reduction: HIV-NAT 085
Generic lopinavir/ritonavir is bioequivalent to Aluvia but neither result in adequate lopinavir exposure at 50% dose reduction: HIV-NAT 085 Reshmie Ramautarsing, Meena Gorowara, Jasper van der Lugt, Jiratchaya
More informationTreatment of Tuberculosis. Dr Sarabjit Chadha The Union
Treatment of Tuberculosis Dr Sarabjit Chadha The Union History of treatment of TB. Believed to be as old as mankind Spinal TB has been diagnosed in Egyptian mummies dating 2400 BC Egyptian medical treatise
More informationClinical pharmacology and therapeutic drug monitoring of first-line anti-tuberculosis drugs Sturkenboom, Marieke Gemma Geertruida
University of Groningen Clinical pharmacology and therapeutic drug monitoring of first-line anti-tuberculosis drugs Sturkenboom, Marieke Gemma Geertruida IMPORTANT NOTE: You are advised to consult the
More informationTRAITEMENT DE MYCOBACTERIUM TUBERCULOSIS MULTIRÉSISTANT
TRAITEMENT DE MYCOBACTERIUM TUBERCULOSIS MULTIRÉSISTANT LORENZO GUGLIELMETTI RICAI, 18 DÉCEMBRE 2017 CNR des Mycobactéries OUTLINE Introduction New regimens and new drugs New drugs in France Future perspectives
More informationPHARMACOTHERAPY OF TUBERCULOSIS MANAGEMENT
PHARMACOTHERAPY OF TUBERCULOSIS MANAGEMENT Rahela Ambaras Khan BPharm (USM), MPharm (Clin.)(UKM), BCPS(US) PhD Student Faculty of Medicine University Malaya OUTLINE Introduction to Tuberculosis Management
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of
More informationComparison of GW (908) Single Dose and Steady-state Pharmacokinetics (PK): Induction Potential and AAG Changes (APV10013)
43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Poster A-1607 Comparison of GW433908 (908) Single Dose and Steady-state Pharmacokinetics (PK): Induction Potential and AAG
More informationDisclosures. Public Health Motivation 6/6/2012. The 12-Dose INH-Rifapentine Once-Weekly DOT Regimen: What Next?
The 12-Dose INH-Rifapentine Once-Weekly DOT Regimen: What Next? NTCA Conference June 14, 2012 John Jereb, FSEB, DTBE, CDC Special thanks to Christine Ho, Elsa Villarino, and Andrey Borisov The findings
More informationPharmacokinetics of Rifampicin in African Children Evaluation of the new WHO dosing guidelines
Pharmacokinetics of Rifampicin in African Children Evaluation of the new WHO dosing guidelines Paolo Denti, Carmen Gonzalez-Martinez, Jana Winckler, Adrie Bekker, Heather Zar, Gerry Davies, Annelies van
More informationTreatment of Tuberculosis
TB Intensive Tyler, Texas June 1-3, 2009 Treatment of Tuberculosis Barbara Seaworth, MD June 3, 2009 Treatment of Tuberculosis Barbara J Seaworth MD Medical Director Heartland National TB Center 1 Purpose
More informationLTBI Treatment and Anti TNF alpha
LTBI Treatment and Anti TNF alpha Therapy Julie Higashi, MD PhD Director, TB Control Section San Francisco Department of Public Health TNF alpha is important for the immune response against TB Macrophages
More informationResearch Excellence to Stop TB Resistance. Plan for MDR-TB Clinical Trials: An Overview March 9, 2010
RESIST-TB: Summary Research Excellence to Stop TB Resistance Plan for MDR-TB Clinical Trials: An Overview March 9, 2010 The current epidemic of Multidrug-Resistant Tuberculosis (MDR-TB) is a major threat
More informationClarithromycin significantly increases linezolid serum concentrations
AAC Accepts, published online ahead of print on 13 September 2010 Antimicrob. Agents Chemother. doi:10.1128/aac.00757-10 Copyright 2010, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of the clinical
More informationToxicity associated with tuberculosis chemotherapy in the REMoxTB study
Tweed et al. BMC Infectious Diseases (2018) 18:317 https://doi.org/10.1186/s12879-018-3230-6 RESEARCH ARTICLE Open Access Toxicity associated with tuberculosis chemotherapy in the REMoxTB study Conor D.
More information